Mesenchymal Stem Cell Lines Isolated by Different Isolation Methods Show Variations in the Regulation of Graft-versus-host Disease |
Yoo, Hyun Seung
(Translational Research Center, Inha University School of Medicine)
Yi, TacGhee (Translational Research Center, Inha University School of Medicine) Cho, Yun Kyoung (HomeoTherapy Co. Ltd.) Kim, Woo Cheol (Department of Radiation Oncology, Inha University School of Medicine) Song, Sun U. (Translational Research Center, Inha University School of Medicine) Jeon, Myung-Shin (Translational Research Center, Inha University School of Medicine) |
1 | Goker, H., I. C. Haznedaroglu, and N. J. Chao. 2001. Acute graft-vs-host disease: pathobiology and management. Exp. Hematol. 29: 259-277. DOI |
2 | Menillo, S. A., S. L. Goldberg, P. McKiernan, and A. L. Pecora. 2001. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow. Transplant. 28: 807-808. DOI |
3 | Deeg, H. J. 2007. How I treat refractory acute GVHD. Blood 109: 4119-4126. DOI |
4 | Rager, A., N. Frey, S. C. Goldstein, R. Reshef, E. O. Hexner, A. Loren, S. M. Luger, A. Perl, D. Tsai, J. Davis, M. Vozniak, J. Smith, E. A. Stadtmauer, and D. L. Porter. 2011. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. Bone Marrow. Transplant. 46: 430-435. DOI |
5 | Schub, N., A. Gunther, A. Schrauder, A. Claviez, C. Ehlert, M. Gramatzki, and R. Repp. 2011. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow. Transplant. 46: 143-147. DOI |
6 | Prockop, D. J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74. DOI |
7 | Branch, M. J., K. Hashmani, P. Dhillon, D. R. Jones, H. S. Dua, and A. Hopkinson. 2012. Mesenchymal stem cells in the human corneal limbal stroma. Invest. Ophthalmol. Vis. Sci. 53: 5109-5116. DOI |
8 | Tse, W. T., J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan. 2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75: 389-397. DOI |
9 | Di Nicola, M., C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti, and A. M. Gianni. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843. DOI |
10 | Jiang, X. X., Y. Zhang, B. Liu, S. X. Zhang, Y. Wu, X. D. Yu, and N. Mao. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-4126. DOI |
11 | Sotiropoulou, P. A., S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem. Cells. 24: 74-85. DOI |
12 | Le Blanc, K., F. Frassoni, L. Ball, F. Locatelli, H. Roelofs, I. Lewis, E. Lanino, B. Sundberg, M. E. Bernardo, M. Remberger, G. Dini, R. M. Egeler, A. Bacigalupo, W. Fibbe, and O. Ringden; Developmental Committee of the European Group for Blood and Marrow Transplantation. 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 371: 1579- 1586. DOI |
13 | Corcione, A., F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia, and A. Uccelli. 2006. Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367-372. DOI |
14 | Glennie, S., I. Soeiro, P. J. Dyson, E. W. Lam, and F. Dazzi. 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105: 2821-2827. DOI |
15 | Le Blanc, K., I. Rasmusson, B. Sundberg, C. Gotherstrom, M. Hassan, M. Uzunel, and O. Ringden. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363: 1439-1441. DOI |
16 | Ringden, O., M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, H. Lonnies, H. U. Marschall, A. Dlugosz, A. Szakos, Z. Hassan, B. Omazic, J. Aschan, L. Barkholt, and K. Le Blanc. 2006. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390- 1397. DOI |
17 | Allison, M. 2009. Genzyme backs osiris, despite prochymal flop. Nat. Biotechnol. 27: 966-967. DOI |
18 | Li, W. J., H. Chiang, T. F. Kuo, H. S. Lee, C. C. Jiang, and R. S. Tuan. 2009. Evaluation of articular cartilage repair using biodegradable nanofibrous scaffolds in a swine model: a pilot study. J. Tissue. Eng. Regen. Med. 3: 1-10. DOI |
19 | Yan, H. and C. Yu. 2007. Repair of full-thickness cartilage defects with cells of different origin in a rabbit model. Arthroscopy 23: 178-187. DOI |
20 | Liao, W., J. Xie, J. Zhong, Y. Liu, L. Du, B. Zhou, J. Xu, P. Liu, S. Yang, J. Wang, Z. Han, and Z. C. Han. 2009. Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation 87: 350-359. DOI |
21 | Bruck, F., L. Belle, C. Lechanteur, L. de Leval, M. Hannon, S. Dubois, E. Castermans, S. Humblet-Baron, S. Rahmouni, Y. Beguin, A. Briquet, and F. Baron. 2013. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy 15: 267-279 DOI |
22 | Song, S. U., C. S. Kim, S. P. Yoon, S. K. Kim, M. H, Lee, J. S. Kang, G. S. Choi, S. H. Moon, M. S. Choi, Y. K. Cho, and B. K. Son. 2008. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem. Cells. Dev. 17: 451-461. DOI |
23 | Jeon, M. S., T. G. Yi, H. J. Lim, S. H. Moon, M. H. Lee, J. S. Kang, C. S. Kim, D. H. Lee, and S. U. Song. 2011. Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method. World. J. Stem. Cells. 3: 70-82. DOI |
24 | Saito, T., J. Q. Kuang, B. Bittira, A. Al-Khaldi, and R. C. Chiu. 2002. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann. Thorac. Surg. 74: 19-24. DOI |
25 | Liechty, K. W., T. C. MacKenzie, A. F. Shaaban, A. Radu, A. M. Moseley, R. Deans, D. R. Marshak, and A. W. Flake. 2000. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat. Med. 6: 1282-1286. DOI |
26 | Sato, K., K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228-234. DOI |
27 | Jeon, M. S., H. J. Lim, T. G. Yi, M. W. Im, H. S. Yoo, J. H. Choi, E. Y. Choi, and S. U. Song. 2010. Xenoreactivity of human clonal mesenchymal stem cells in a major histocompatibility complex-matched allogeneic graft-versus-host disease mouse model. Cell. Immunol. 261: 57-63. DOI |
28 | Ren, G., L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, and Y. Shi. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell. Stem. Cell. 2: 141-150. DOI |
29 | Dazzi, F. and F. M. Marelli-Berg. 2008. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. Eur. J. Immunol. 38: 1479-1482. DOI |
30 | Katz, J. B., A. J. Muller, and G. C. Prendergast. 2008. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222: 206-221. DOI |
31 | Baron, F. and R. Storb. 2012. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol. Blood Marrow. Transplant. 18: 822-840. DOI |
32 | Sudres, M., F. Norol, A. Trenado, S. Gregoire, F. Charlotte, B. Levacher, J. J. Lataillade, P. Bourin, X. Holy, J. P. Vernant, D. Klatzmann, and J. L. Cohen. 2006. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176: 7761-7767. DOI |
33 | Polchert, D., J. Sobinsky, G. Douglas, M. Kidd, A. Moadsiri, E. Reina, K. Genrich, S. Mehrotra, S. Setty, B. Smith, and A. Bartholomew. 2008. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38: 1745-1755. DOI |
34 | Jang, M. J., H. S. Kim, H. G. Lee, G. J. Kim, H. G. Jeon, H. S. Shin, S. K. Chang, G. H. Hur, S. Y. Chong, D. Oh, and H. M. Chung. 2013. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice. Acta. Haematol. 129: 197-206 DOI |
35 | Yanez, R., M. L. Lamana, J. Garcia-Castro, I. Colmenero, M. Ramirez, and J. A. Bueren. 2006. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem. Cells. 24: 2582-2591. DOI |